Maha FDA: PPE manufacturers directed to test & certify PPE kits in Mumbai-based labs

The Maharashtra Food and Drug Administration (FDA) has directed the PPE manufacturers to test and certify PPE kits in Mumbai-based labs as per Union health ministry guidelines. The Maha FDA has conducted a total of 1945 inspections on personal protective equipment (PPE) kit manufacturers to check the quality of these products till date.

Maharashtra FDA earlier had directed its joint commissioners, assistant commissioners and district level drug control officers to review and oversee the 19 PPE manufacturers in the state for quality compliance. These manufacturers, who have a production capacity ranging from 500 to 15,000 PPE kits daily, are based in Sangli, Pimpri, Nashik, Navi Mumbai, Vasai, Andheri, Mulund, Palghar, Bhiwandi and Bhayander areas of the state.

The Central government had notified EC Order, 2020 to regulate production, quality, distribution and logistics of masks (2ply and 3ply surgical masks, N95 masks) which are part of PPE for COVID-19 management. There are two types of masks which are recommended for various categories of personnel working in hospital or community settings, depending upon the work environment – triple layer medical mask and N-95 respirator mask.

An advisory had also been issued by The Drugs Controller General of India (DCGI) to the PPE manufacturers to voluntarily register under the medical device rules, 2017. The registration will secure the manufacturers a registration number from the CDSCO, which will serve as a quality management system benchmark.

As of today, 107 PPE manufacturers have been approved by the Central Drugs Standard Control Organisation (CDSCO) for supplies in the government healthcare institutions. CDSCO has also directed all approved PPE manufacturers to voluntarily register at its medical device online portal—cdscomdonline.gov.in for quality compliance and to create a database of authentic manufacturers in the country.

  • Related Posts

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?